TPTX News and Press, Turning Point Therapeutics Inc. From 06/28/22

Bristol-Myers hits new highs, partly due to investors piling into drug stocks with the economy facing a potential recession. The biopharma faces the loss of exclusivity, or LOE, on its largest drug Revlimid while launching new drugs with the potential to replace the lost revenues of t...

HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today a...

NEW YORK, NY / ACCESSWIRE / June 23, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Turning Point Therapeutics, Inc. (NA...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Another week and another deal with big pharma buying out a development stage oncology company. Turning Point Therapeutics entered into an agreement to be acquired by Bristol Myers Squibb. Bristol Myers Squibb expects repotrectinib, Turning Point's lead candidate to be approved in ...

Bristol-Myers Squibb (NYSE:BMY) has withdrawn a supplemental Biologics License Application for Reblozyl (luspatercept) for anemia with non-transfusion dependent beta thalassemia. The pharma said it was doing so as it could not address questions posed by the U.S. FDA on the risk-benefit profil...

Wall Street suffered renewed selling on Friday, as worries about the economy and interest rates resurfaced. Stronger-than-expected job statistics raised fears that the Federal Reserve would remain aggressive about raising interest rates. Meanwhile, Elon Musk sounded the latest in a series of ...

Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...

Update 12:15pm: Updates shares, adds other potential names benefitting from the deal. Blueprint Medicines (NASDAQ:BPMC) rose 4% after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) c...

Turning Point Therapeutics Inc ( NASDAQ: TPTX ) jumped 110% after announcing a definitive merger agreement with Bristol Myers Squibb Co ( NYSE: BMY ) . Under the agreement, Bristol Myers Squibb will acquire Turning Point at $76 per share. The Board of Directors of both T...